Elucid Raises $55M Series D for AI Heart Diagnostics

Boston, MA – Elucid, a pioneer in artificial intelligence for cardiovascular diagnostics, has successfully closed an oversubscribed $55 million Series D funding round. This significant capital infusion propels the company's total funding to approximately $185 million, underscoring robust investor confidence in its innovative approach to non-invasive cardiac risk assessment.

The latest financing round saw substantial participation from a major medical technology corporation, marking its entry as Elucid's fourth publicly traded strategic partner. This strategic alignment highlights the growing industry recognition of Elucid's AI-driven software in enhancing the precision of cardiovascular disease diagnosis and treatment planning. The syndicate also welcomed new and existing investors, including IAG Capital Partners and Elevage Medical Technologies, a platform established by Patient Square Capital.

Proceeds from this Series D will be strategically deployed to accelerate the commercial rollout of Elucid's comprehensive clinical platform. Key areas of expansion include the FFR-CT (Flow Fraction Reserve – Computed Tomography) technology, currently awaiting FDA 510(k) clearance, and its established Plaque-IQ™ software. The funding will also fuel continued investment in novel AI research and development, alongside support for landmark clinical studies aimed at advancing the understanding and management of cardiovascular conditions.

Elucid's core mission revolves around leveraging AI to reveal subtle indicators of cardiovascular risk that are often missed by conventional methods. The company's clinical platform is designed to empower physicians with a more granular view of atherosclerosis, the primary driver of heart disease. By providing a clearer picture of arterial plaque, Elucid's FDA-cleared Plaque-IQ™ software enables clinicians to tailor treatment strategies based on the actual presence and severity of disease, moving beyond generalized risk stratification models.

The Plaque-IQ™ solution offers critical insights into the composition and volume of arterial plaque, which are key determinants for potential heart attack and stroke events. Furthermore, Elucid is actively pursuing an indication for its BioIntegrated FFR-CT product. This technology aims to non-invasively identify coronary blockages and quantify the extent of myocardial ischemia by integrating anatomical, plaque biological, and physiological data, demonstrating strong concordance with its plaque analysis algorithms.

The cardiovascular disease market is a significant area of focus within the broader healthcare sector, with advancements in diagnostic technology playing a crucial role. The increasing prevalence of heart disease globally, coupled with the drive for more personalized and efficient patient care, creates a fertile ground for AI-powered solutions like Elucid's. This funding round positions Elucid to further solidify its leadership in this critical medical technology segment.